Ascend gains a 650M-param, Apache 2.0 ESM-1v for zero-shot protein prediction. Yet, it's a legacy architecture, superseded by ESM-2, and a single model reduces accuracy. Unlikely this truly competes with full ESM-2 ensembles for cutting-edge drug discovery.